ClinicalTrials.gg
CompletedNCT03275922Updated Jan 11, 2021

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

A Phase 3 interventional study of Placebo ZNS and ZNS in Migraine, sponsored by Impax Laboratories, LLC. Completed at 47 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
134th of 609
374 · median 78
Started
2017
with 45 others
Phase 3
136 of 696
20 open now
Registered
366th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 134th largest by enrollment of the 609 interventional ones that give a count, is one of 46 that started in 2017, is one of 136 in phase 3, and was the 366th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years.

Part 1: Approximately 20 weeks (includes screening and double-blind treatment).

  • Screening will be performed based on the inclusion exclusion criteria specified in the study protocol.
  • Randomize approximately 288 subjects into the double-blind crossover phase.

Part 2: Approximately 100 subjects who complete the double-blind crossover phase will enter part 2, a 6 month open-label safety extension (OLE).

Efficacy will be evaluated in the double-blind part of the trial. Safety will be evaluated in both the double-blind and the OLE.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Headache
  • Pain
  • Efficacy
  • Pediatric
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Parent or legal guardian is able to provide written and subject is able to provide assent.
  2. Subjects ages 6 to 11 years throughout the double-blind portion of the studyAn established diagnosis of migraine
  3. By history, average migraine frequency of ≥ 2 attacks per month lasting on average ≥ 3 hours per attack
  4. By history, experiences at least 16 headache-free days per month on average

Exclusion criteria

Exclusion Criteria:

  1. History of ischemic or vasospastic heart disease, arrhythmias associated with accessory conduction pathways (eg, Wolff-Parkinson-White syndrome), cerebrovascular disease, hemiplegic or basilar artery migraine, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, recent (within 24 hours) or use of another 5HT1 agonist, ergots or ergotamine-containing medications.
  2. Any medical condition, including severe hepatic impairment, which, in the opinion of the investigator, may put the subject at increased risk with exposure to zolmitriptan, or may interfere with the safety or efficacy assessments.
  3. Had an unacceptable adverse experience following previous use of any 5HT1B/1D agonist drug (in the opinion of the investigator).
  4. Had not experienced satisfactory relief from migraine pain during prior treatment with 2 or more adequate courses of triptans.
  5. Prior use of any nasal spray (triptan or dihydroergotamine [DHE]) for the acute treatment of migraine
  6. Disease or anatomic abnormalities of the nasal cavity precluding or complicating the use of ZNS.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
374 participants (actual)

Study arms

  • Other
    Run-in - ZNS - Placebo - OLE

    After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).

    Drug: Placebo ZNS · Drug: ZNS

  • Other
    Run-in - Placebo - ZNS - OLE

    After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).

    Drug: Placebo ZNS · Drug: ZNS

Interventions

  • DrugPlacebo ZNS

    Placebo Zolmitriptan Nasal Spray

    Also known as: Placebo

  • DrugZNS

    Zolmitriptan Nasal Spray

06

What researchers measure

Primary outcomes

  1. Pain-free status at 2 hours post treatment

    Headache pain intensity is assessed by the subjects immediately prior to treatment and 2 hours post-dose using a 4-point headache pain intensity scale (severe = 3, moderate = 2, mild = 1, or none = 0).

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Proportion of subjects who achieve pain-free status at 24 hours post-dose

    The headache pain intensity is assessed by the subjects using a 4-point headache pain intensity scale (severe = 3, moderate = 2, mild = 1, or none = 0).

    Time frame: 24 hours post-dose

  2. Headache response at 24 hours post-dose

    The subject diary captures the headache severity using a 4-point headache pain intensity scale (severe = 3, moderate = 2, mild = 1, or none = 0). Headache response is defined as a reduction in moderate (2) or severe (3) pain to mild (1) or no (0) pain at 24 hour post-dose.

    Time frame: 24 hours post-dose

  3. Sustained headache response at 24 hours post-dose

    Sustained headache response is defined as a reduction in migraine headache pain intensity from severe or moderate to mild or none at 2 hours which is then maintained (without a return to moderate or severe pain) at 24 hours with no use of rescue medication prior to the 24 hour assessment.

    Time frame: 24 hours post-dose

07

Study locations

47 sites
  • Phoenix Children's Hospital (149)
    Phoenix, Arizona 85016, United States
  • Arkansas Children's Hospital (109)
    Little Rock, Arkansas 72202, United States
  • Advanced Research Center, Inc (134)
    Anaheim, California 92805, United States
  • Sierra Medical Research (124)
    Fresno, California 17601, United States
  • Shailesh M. Asaikar, MD. Inc. DBA Child and Adolescent Neurology Consultatns (119)
    Sacramento, California 95815, United States
  • Children's Hospital Colorado (154)
    Aurora, Colorado 80045, United States
  • Blue Sky Neurology (106)
    Englewood, Colorado 80113, United States
  • IMMUNOe Research Centers (150)
    Thornton, Colorado 80233, United States
  • Ki Health Partners, LLC dba New England INstitute for Clinical Research (128)
    Stamford, Connecticut 06905, United States
  • Children's National Health System (141)
    Washington, District of Columbia 20010, United States
  • NW Florida Clinical Research Group, LLC (122)
    Gulf Breeze, Florida 32561, United States
  • Clinical Neuroscience Solutions, Inc. (127)
    Jacksonville, Florida 32256, United States
  • Axcess Medical Research (126)
    Loxahatchee Groves, Florida 33470, United States
  • Biotech Pharmaceutical Group (138)
    Miami, Florida 33155, United States
  • Sanitas Medical and Dental Institute/dba Sanitas Research, LLC (142)
    Miami, Florida 33155, United States
  • Laszlo J. Mate, M.D., P.A. (153)
    North Palm Beach, Florida 33408, United States
  • Clincial Neuroscience Solutions, Inc. (136)
    Orlando, Florida 32801, United States
  • Pediatric Neurology, PA (125)
    Orlando, Florida 32819, United States
  • East Florida Research (143)
    Port Saint Lucie, Florida 34983, United States
  • Pedatric Epilepsy & Neurology Specialists (157)
    Tampa, Florida 17601, United States
  • Premiere Research Institute @ Palm Beach Neurology, PA (105)
    West Palm Beach, Florida 33407, United States
  • Clinical Integrative Research Center of Atlanta (121)
    Atlanta, Georgia 30328, United States
  • NuDirections Clinical Research, LLC (159)
    Atlanta, Georgia 30350, United States
  • iResearch Atlanta, LLC (146)
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research, LLC (130)
    Savannah, Georgia 31406, United States
  • Josephson Wallack Munshower Neurology P.C. (114)
    Indianapolis, Indiana 46256, United States
  • Kosair Charities Pediatric Clinical Research Unit (120)
    Louisville, Kentucky 40202, United States
  • Michigan Head-Pain and Neurological Institute (103)
    Ann Arbor, Michigan 48104, United States
  • Mercy Research (116)
    Saint Louis, Missouri 63141, United States
  • Clinical Research Center of NJ (123)
    Voorhees, New Jersey 08043, United States
  • Dent Neurosciences Research Center (129)
    Amherst, New York 14226, United States
  • OnSite Clinical Solutions, LLC (155)
    Charlotte, North Carolina 28277, United States
  • Headache Wellness Center (Site 152)
    Greensboro, North Carolina 27405, United States
  • Raleigh Neurology Associates, PA (113)
    Raleigh, North Carolina 27607, United States
  • Akron Children's Hospital (site 139)
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital (140)
    Cincinnati, Ohio 45229, United States
  • Preferred Primary Care Physicians, Inc. (115)
    Pittsburgh, Pennsylvania 15236, United States
  • Access Clinical Trials, Inc. (151)
    Nashville, Tennessee 37203, United States
  • Texas Neurology, P.A. (110)
    Dallas, Texas 75214, United States
  • Children's Medical Center Dallas (147)
    Dallas, Texas 75235, United States
  • J. Lewis Research Inc. Foothill Family Clinic (107)
    Salt Lake City, Utah 84109, United States
  • Primary Children's Hospital Outpatient Services (117)
    Salt Lake City, Utah 84113, United States
  • Granger Medical Holladay (111)
    Salt Lake City, Utah 84117, United States
  • Pediatric Research of Charlottesville, LLC (104)
    Charlottesville, Virginia 22902, United States
  • Northwest Clinical Research Center (132)
    Bellevue, Washington 98007, United States
  • Multicare Health System- Mary Bridge Pediatrics- Tacoma (158)
    Tacoma, Washington 98405, United States
  • Marshfield Clinic (145)
    Marshfield, Wisconsin 54449, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2020, 31 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2017
First posted
Sep 8, 2017
StartActual
Nov 27, 2017
Primary completionActual
Jul 2, 2020
CompletionActual
Sep 28, 2020
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03275922
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Nov 27, 2017
Primary completion
Jul 2, 2020
Completion
Sep 28, 2020
Last update
Jan 11, 2021

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zonisamide

Start the discussion